title: Immuno-PET for Clinical Theranostic Approaches.
abstract: Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals.
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. clement.bailly@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. clement.bailly@chu-nantes.fr.
authors.forename: Clément
authors.initials: C
authors.lastname: Bailly
authors.affiliation: Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. pf7.clery@gmail.com.
authors.forename: Pierre-François
authors.initials: PF
authors.lastname: Cléry
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. alain.faivre-chauvet@univ-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. alain.faivre-chauvet@univ-nantes.fr.
authors.forename: Alain
authors.initials: A
authors.lastname: Faivre-Chauvet
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. mickael.bourgeois@nantes.inserm.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. mickael.bourgeois@nantes.inserm.fr.
authors.forename: Mickael
authors.initials: M
authors.lastname: Bourgeois
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. francois.guerard@univ-nantes.fr.
authors.forename: François
authors.initials: F
authors.lastname: Guérard
authors.affiliation: Groupement d'Intérêt Public Arronax, 1, rue Aronnax, CS 10112, 44817 Saint-Herblain, France. ferid.haddad@univ-nantes.fr.
authors.forename: Ferid
authors.initials: F
authors.lastname: Haddad
authors.affiliation: Groupement d'Intérêt Public Arronax, 1, rue Aronnax, CS 10112, 44817 Saint-Herblain, France. jacques.barbet@univ-nantes.fr.
authors.forename: Jacques
authors.initials: J
authors.lastname: Barbet
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. michel.cherel@univ-nantes.fr.|Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France. michel.cherel@univ-nantes.fr.
authors.forename: Michel
authors.initials: M
authors.lastname: Chérel
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. francoise.bodere@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. francoise.bodere@chu-nantes.fr.|Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France. francoise.bodere@chu-nantes.fr.
authors.forename: Françoise
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. thomas.carlier@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. thomas.carlier@chu-nantes.fr.
authors.forename: Thomas
authors.initials: T
authors.lastname: Carlier
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France. caroline.milin@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. caroline.milin@chu-nantes.fr.
authors.forename: Caroline
authors.initials: C
authors.lastname: Bodet-Milin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals
chemical_list: D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals
keywords: antibody; immuno-PET; molecular imaging